Better Health for All

SAB Biotherapeutics' core business is developing antibody therapeutics to treat diseases, including Type 1 Diabetes (T1D), influenza, COVID-19, autoimmune disorders, and cancer, indicating an entire business devoted to health improvement. A lead product candidate, SAB-142, a potential disease-modifying treatment for T1D, has shown positive topline Phase 1 clinical results.

The development of disease-modifying treatments like SAB-142 is explicitly stated as a preventative approach, demonstrating a revolutionary focus on disease prevention. The Phase 1 clinical trial for SAB-142 was designed as randomized, double-blind, and placebo-controlled, and received ethical approval from the Australian Human Research Ethics Committee (HREC), reflecting strong ethical standards in clinical trials.

Fair Pay & Worker Respect

No specific quantitative data or substantiated incidents were found across the provided articles for any of the KPIs related to Fair Pay & Worker Respect. While the company has a Code of Conduct and Ethics that addresses discrimination, harassment, and safety, and a complaint procedure for accounting and auditing matters, these documents do not provide measurable outcomes such as living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rates (TRIR), pay equity ratios, worker engagement scores, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage percentages for the workforce.

The company does conform to the ISO 45001:2018 standard for health and safety, but this is a management system certification, not a safety incident rate.

Honest & Fair Business

The company has a whistleblower policy, adopted in November 2021

, allowing confidential and anonymous submissions via a secure webform, telephone hotline, mail, or directly to outside counsel . The policy prohibits retaliation , and a tracking code is provided for message status . The Chief Compliance Officer provides quarterly reports of complaints to the Audit Committee, which oversees investigations . The company restated its financial statements three times in 2021 (January 14, March 31, and June 30) due to misapplication of accounting guidance for warrants and classification of redeemable common shares . A material weakness in internal control over financial reporting related to warrant accounting was identified . A majority of the Board consists of directors determined to be independent under Nasdaq standards . The company has an anti-corruption policy with a zero-tolerance approach to bribery and corruption , including facilitation payments, and requires compliance with laws like the FCPA . However, the policy's training frequency and effectiveness metrics are not specified.

No War, No Weapons

SAB Biotherapeutics has a contract with the U.S. Department of Defense (DoD) for a pharmaceutical platform technology to produce antibody-based Medical Countermeasures (MCM) for biological threats.

This technology has both civilian and military applications. The company's primary focus is on developing antibodies to treat diseases, including infectious diseases like COVID-19, which was a significant part of the DoD funding, suggesting a prioritization of civilian applications for this dual-use R&D.

Planet-Friendly Business

In 2023, the company's total Scope 1, 2, and 3 greenhouse gas emissions were 587,521 tCO₂e, an increase from 533,189 tCO₂e in 2022.

The company's new headquarters achieved LEED Gold and Smartscore Platinum certifications. In 2023, 13.2 tonnes of paper were recycled, up from 7.2 tonnes in 2022. Total waste produced was 44.9 tonnes in 2023, a slight decrease from 45.1 tonnes in 2022. The company reported 21 non-compliance incidents in 2023, down from 26 in 2022. Water consumption was 119,772 m³ in 2023. The company has a net-zero target year of 2040, but interim targets are undefined.

Safe & Smart Tech

The company's privacy policy, effective July 1, 2014, states that users can opt out of receiving certain emails, but the company does not recognize automated browser signals regarding tracking, including “do-not-track” signals, indicating basic data control options with significant limitations.

The company faces potential legal and compliance risks related to healthcare laws and regulations, including stringent approval processes for genetic modification of animals and potential changes in FDA policies, suggesting basic compliance with major regulations but with gaps. SAB Biotherapeutics conducts security assessments of all third-party providers before engagement and has a well-defined written procedure for cybersecurity incidents, with the IT department implementing and overseeing regular monitoring of information systems. However, no information is provided on the average time to patch critical vulnerabilities. The company does not explicitly mention a bug bounty program, indicating a basic or no program. While the company maintains physical, electronic, and procedural safeguards, and its privacy policy is effective July 1, 2014, there is no explicit evidence of privacy principles being integrated throughout the product development lifecycle. The company conducts security assessments of third-party providers, but the scope and frequency of security testing across its own products and services are not specified.

Zero Waste & Sustainable Products

SAB Biotherapeutics, Inc. is required to establish and manage a hazardous waste stream, including separate accounts and waste receptacles, utilizing an appropriate vendor.

The company is also responsible for abating, remedying, and removing any hazardous material discovered on its leased premises that was generated or released by its operations, and for the costs associated with the landlord's treatment of its generated sewage. The company states it strictly complies with all applicable Federal and State environmental laws and regulations, including the Resource Conservation and Recovery Act, and considers sustainability in its planning decisions. No waste disposal violations, regulatory actions, or fines related to waste management or sustainability are mentioned in the provided documents.